Bio-Works Technologies

The Chairman of the Board of Bio-Works Technologies AB, Peter Ehrenheim, Board Members Jonas Ahlén and Thomas Gür, together with CEO Lone Carlbom, have jointly announced their intention to exercise all of their outstanding Warrants of series TO 2 at the forthcoming exercise period.

The combined holding amounts to 1,496,092 TO 2 Warrants. The next exercise period runs from 1–14 October 2025.

Upon exercise, Bio-Works will receive SEK 1,496,092 before issue costs.

Board Member Peter Nälstedt exercised his TO 2 Warrants in April 2025.

Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Peter Ehrenheim, Chairman, e-mail: peter@farjsundet.se, phone: +46 (70) 667 5711.

For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Arne Hauge, CFO, e-mail: arne.hauge@bio-works.com, phone: +46(0)8-502 705 83.

About Bio-Works
Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.

Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market ("BIOWKS"). For more information, visit www.bio-works.com.